InflaRx NV
NASDAQ:IFRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value for InflaRx NV.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What InflaRx Does
InflaRx NV is a clinical-stage biopharmaceutical company that develops medicines for inflammatory and autoimmune diseases. Its main approach is to block a part of the immune system called complement, especially the C5a pathway, which can drive harmful inflammation in conditions where the body attacks its own tissues.
- Headquarters
- Germany DE
- Employees
- 65
- IPO date
- Nov 8, 2017